|Application ||IHC-P, WB|
|Calculated MW||H=57;M=57 KDa|
|Other Names||Dihydropyrimidinase, DHP, DHPase, Dihydropyrimidine amidohydrolase, Hydantoinase, DPYS|
|Target/Specificity||This DPYS antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 454-482 amino acids from the C-terminal region of human DPYS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||DPYS Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyze the ring opening of 5,6- dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.|
|Tissue Location||Liver and kidney.|
Provided below are standard protocols that you may find useful for product applications.
Dihydropyrimidinase catalyzes the conversion of 5,6-dihydrouracil to 3-ureidopropionate in pyrimidine metabolism. Dihydropyrimidinase is expressed at a high level in liver and kidney as a major 2.5-kb transcript and a minor 3.8-kb transcript. Defects in the DPYS gene are linked to dihydropyrimidinuria.
Kim, H.Y., et al. BMB Rep 43(8):547-553(2010)
van Kuilenburg, A.B., et al. Biochim. Biophys. Acta 1802 (7-8), 639-648 (2010) :
Fidlerova, J., et al. Cancer Chemother. Pharmacol. 65(4):661-669(2010)
Thomas, H.R., et al. Pharmacogenet. Genomics 18(1):25-35(2008)
Thomas, H.R., et al. Pharmacogenet. Genomics 17(11):973-987(2007)